Caribou Biosciences, Inc.
HealthcareNASDAQ:CRBU · NASDAQ Global Select
-$0.07 today
Vol 2.29M · Avg 1.51M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-121.2%
avg -60.8%
ROIC
-89.8%
avg -59.2%
ROA
-84.5%
avg -47.2%
Analysis
ROA is currently the strongest return metric at -84.5% versus its period average of -47.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Rachel E. Haurwitz | Co-Founder, Chief Executive Officer, President & Director | $993,606.00 | — | 40 | $682,500.00 | 0.69% |
Timothy Kelly | Chief Technology Officer | $730,050.00 | — | 56 | $73,125.00 | 0.07% |
Barbara G. McClung | Chief Legal Officer & Corporate Secretary | $686,720.00 | — | 71 | $481,564.00 | 0.49% |
Tina Albertson | Chief Medical Officer | $677,076.00 | — | 52 | $68,523.00 | 0.07% |
Sriram Ryali | Chief Financial Officer | $663,512.00 | — | 44 | $72,360.00 | 0.07% |
Ruhi A. Khan | Chief Business Officer | $573,900.00 | — | 50 | $104,998.00 | 0.11% |
Jennifer A. Doudna | Co-founder & Member of Scientific Advisory Board | — | — | 62 | — | — |
Ryan Fischesser | Interim Principal Accounting Officer & Controller | — | — | — | $118,854.00 | 0.12% |
Reigin Zawadzki | Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
5
$47,474.48
Net Sentiment
$47,474.48
Net selling
Most Active
Kelly Timothy P
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 5 sells worth $47,474.48 over the last 12 months. That adds up to net selling of $47,474.48. Kelly Timothy P was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +40.8% | +21.0% (7yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +40.8% over three years. Forward estimates point to Revenue at +21.0% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Inventiva S.A.
NASDAQ:IVA
$200.13M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
Who manages CRBU?
Caribou Biosciences, Inc. (CRBU) lists 9 active executives. The top listed executive is Barbara G. McClung, Chief Legal Officer & Corporate Secretary.
Are CRBU insiders buying or selling?
Recent insider activity shows net buying of $52.25M.
Explore More
Continue the stock analysis
Jump to another research area for this company.